The Online Investor
NuCana Plc (NCNA)

NuCana is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by applying its ProTide™ technology to transform some of the prescribed chemotherapy agents, nucleoside analogs, into medicines. Utilizing its proprietary technology, Co. is developing new medicines, ProTides, designed to overcome main cancer resistance mechanisms and generate concentrations of anti-cancer metabolites in cancer cells. Co.'s ProTide candidates, Acelarin® and NUC-3373, are chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two chemotherapy agents. Co. is evaluating NUC-7738 in clinical trial for patients with solid tumors.
Company Name: 
NuCana Plc
Website: 
www.nucana.com
Sector: 
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree NCNA Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.60 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)

Analysts' Target Price:
NCNA Stock Forecast

Based on Zacks ABR data;
powered by Xignite

NuCana Plc (NCNA) Page | The Online Investor Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2024, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.